Lugano, Switzerland, December 21, 2021 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announced that the European Medicines Agency (EMA) accepted for review the Company’s Marketing Authorization Application (MAA) for infigratinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. The EMA’s acceptance for review of the MAA confirms that the submission is complete and the formal review process can begin. In March 2021, Helsinn Group entered a strategic collaboration with QED Therapeutics, an affiliate company of BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, to co-develop and co-commercialize infigratinib in oncology indications worldwide except in China, Hong Kong and Macau.

Sergio Cantoreggi, Helsinn Group Chief Scientific Officer and Global Head of R&D, commented: “The acceptance for review of our MAA is a significant step towards bringing infigratinib to patients in the European Union. There is a great need for new therapies in bile duct cancer for patients who have relapsed after first-line therapy and need further targeted treatment. This acceptance opens the review process for infigratinib and we look forward to working closely with the EMA to potentially bring this novel therapy to patients in need.’’

About Infigratinib
Infigratinib is a potent orally administered, selective, ATP‐competitive, kinase inhibitor of FGFRs, with highest affinity for FGFR 1, 2, and 3. The therapy is currently in development in oncology for the treatment of individuals with FGFR2-altered cholangiocarcinoma (bile duct cancer) and FGFR3-altered urothelial carcinoma (bladder cancer) and in skeletal dysplasias for the treatment of individuals with FGFR3-altered achondroplasia. BridgeBio retains full rights to infigratinib in skeletal dysplasias for the treatment of individuals with FGFR3-altered achondroplasia.
For details on approvals by Health Authorities, please visit to access product details. Product labeling from various countries or regions may differ based on the study design requirements of the Health Authority for the respective jurisdiction.

About Cholangiocarcinoma (CCA)
CCA (bile duct cancer) represents an aggressive group of malignancies that form in the bile ducts. The incidence of this serious and fatal disease varies considerably worldwide. As the disease is usually asymptomatic at early-stages, CCA typically presents at diagnosis as locally advanced or metastatic disease with a poor prognosis. FGFR2 genetic aberrations are present in approximately 15% to 20% of people who have this disease. Currently, the five-year survival rate is only 9%.1

Download the PR here:

Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements

pdf 198KB